The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2

J. W. Baars, C. E. Hack, J. Wagstaff, A. J M Eerenberg-Belmer, G. J. Wolbink, L. G. Thijs, R. J M Strack van Schijndel, H. L J A van der Vall, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The toxicity due to interleukin-2 (IL-2) strongly resembles the clinical picture seen during septic shock. In septic shock activation of polymorphonuclear neutrophils (PMN) and the complement system contribute significantly to the pathophysiology of the condition. We therefore investigated whether similar events contributed to the toxicity observed with IL-2. Four patients received seven cycles of escalating dose IL-2 (18.0 to 72.0 x 106 1Um-2 day-1) and 16 were treated with 20 cycles of fixed dose IL-2 (12.0 or 18.0 x 106 1Um-2 day-1). Toxicity, as judged by hypotension (P=-1; P=1A) and lactoferrin values of 212 (SEM=37) and 534 (SEM=92) ng ml-1 respectively occurring 6h after the IL-2. Peak values for the esc. dose IL-2 group being generally higher than 500ng ml-1. Activation of thc complement cascade was evidenced by a dose dependent elevation of peak C3a values (fixed dose 9.1 (SEM=0.6), esc. dose 25.7 (SEM=6.33); P=

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalBritish Journal of Cancer
Volume65
Issue number1
StatePublished - 1992
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baars, J. W., Hack, C. E., Wagstaff, J., Eerenberg-Belmer, A. J. M., Wolbink, G. J., Thijs, L. G., Strack van Schijndel, R. J. M., van der Vall, H. L. J. A., & Pinedo, H. M. (1992). The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. British Journal of Cancer, 65(1), 96-101.